Overview
- 50 inspections across 46 sites are on record.
- 54 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-06-16.
At a glance
Inspections
50
Sites
46
Observations
54
Career since
May 2021
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Luoxin Aurovitas Pharma (Chengdu) Co., Ltd | 16 Jun 2026 | Human Drugs | On file |
| Apnar Pharma LLP | 22 May 2026 | Human Drugs | View 483 → |
| MSN PHARMACEUTICALS INC. | 13 Mar 2026 | Human Drugs | |
| Fresenius Kabi USA, LLC | 13 Feb 2026 | Human Drugs | On file |
| Hebei Meishen Technology Co., Ltd. | 18 Dec 2025 | Human Drugs | On file |
Sites inspected
Luoxin Aurovitas Pharma (Chengdu) Co., LtdChengdu, China1 insp.
Apnar Pharma LLPEast Windsor, United States1 insp.
MSN PHARMACEUTICALS INC.Piscataway, United States1 insp.
Fresenius Kabi USA, LLCWilson, United States1 insp.
Hebei Meishen Technology Co., Ltd.Xingtai, China1 insp.
Co-investigators
Investigators who share inspections with this person.
Robin P Mathew5 shared
Bijoy Panicker4 shared
James R Birkenstamm3 shared
Russell J Glapion3 shared
Karishma G Gopaul2 shared
Yvins Dezan2 shared
Ko U Min2 shared
Adetutu M Gidado2 shared
Amatul H Marium1 shared
Vivin George1 shared
Full investigator report
Get the verbatim findings behind Ankur C Patel's 54 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site